Investigational drug · Phase 2
EXG202
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Wet Age-related Macular Degeneration.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "EXG202"
First trial start
2025
Oct 16, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EXG202", any sponsor or status.
Conditions studied
As listed on its trial records.
- Wet Age-related Macular Degeneration
Approved drugs for the same conditions: Wet macular degeneration · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "EXG202" as an intervention, largest first.
- Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMDNot yet recruiting
Guangzhou Jiayin Biotech LtdIndustry
NCT07178249 · 60 participants (planned) · Start Oct 16, 2025 · Primary completion Feb 28, 2028
Drug: EXG202 injection · For: Wet Age-related Macular Degeneration
- To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)Not yet recruiting
Guangzhou Jiayin Biotech LtdIndustry
NCT06888492 · 8 participants (planned) · Start Mar 28, 2025 · Primary completion Apr 25, 2026
Drug: EXG202 · For: Wet Age-related Macular Degeneration (wAMD); Wet Age-related Macular Degeneration
Sites: Xingtai, China; Yiwu, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Wet Age-related Macular Degeneration
- OLN324Phase 34 trials
Ollin Biosciences, Inc. · Diabetic Macular Edema (DME), Wet Age Related Macular Degeneration, Wet Age-related Macular Degeneration
- Tabirafusp tedromerKSI-501Phase 32 trials
Kodiak Sciences Inc · Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration
- TarcocimabTarcocimab tedromer, KSI-301Phase 32 trials
Kodiak Sciences Inc · Wet Age-related Macular Degeneration, Diabetic Retinopathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.